Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
1994-12-9
|
pubmed:abstractText |
The biodistribution of indium-111/yttrium-88-labeled B3 monoclonal antibody, a murine IgG1k, was evaluated in non-tumor-bearing mice. B3 was conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M) or 2-(p-SCN-Bz)-1,4,7,10 tetraazacyclododecane tetra-acetic acid (2B-DOTA) and labeled with 111In at 1.4-2.4 mCi/mg and 88Y at 0.1-0.3 mCi/mg. Non-tumor-bearing nude mice were co-injected i.v. with 5-10 microCi/4-10 micrograms of 111In/88Y-labeled B3 conjugates and sacrificed at 6 h and daily up to 168 h post-injection. Mice injected with 111In/88Y-(1B4M)-B3 showed a similar biodistribution of the two radiolabels in all tissues except the bones, where significantly higher accretion of 88Y than 111In was observed, with 2.8% +/- 0.2% vs 1.3% +/- 0.16% ID/g in the femur at 168 h, respectively (P < 0.0001). In contrast, mice receiving the 111In/88Y-(DOTA)-B3 conjugate showed significantly higher accumulation of 111In than 88Y in most tissues, including the bones, with 2.0% +/- 0.1% vs 1.2% +/- 0.09% ID/g in the femur at 168 h, respectively (P < 0.0001). Whereas the ratios of the areas underneath the curve (%ID x h/g) in the blood, liver, kidney and bone were 0.96, 1.12, 1.13, and 0.74 for 111In/88Y-(1B4M)-B3 and 0.84, 1.23, 1.56, and 1.31 for 111In/88Y-(DOTA)-B3, respectively, ratios approximately 1 were observed between 111In-(1B4M)-B3 and 88Y-(DOTA)-B3. In summary, while neither 1B4M nor DOTA was equally stable for 111In and 88Y, the fate of 88Y-(DOTA)-B3 could be closely traced by that of 111In-(1B4M)-B3.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2-(4-isothiocyanatobenzyl)-1,4,7,10-...,
http://linkedlifedata.com/resource/pubmed/chemical/2-(4-isothiocyanatobenzyl)-6-methyld...,
http://linkedlifedata.com/resource/pubmed/chemical/Chelating Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Heterocyclic Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Indium Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/Isothiocyanates,
http://linkedlifedata.com/resource/pubmed/chemical/Pentetic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Yttrium Radioisotopes
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0340-6997
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
21
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
N
|
pubmed:pagination |
640-6
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:7957350-Animals,
pubmed-meshheading:7957350-Chelating Agents,
pubmed-meshheading:7957350-Female,
pubmed-meshheading:7957350-Heterocyclic Compounds,
pubmed-meshheading:7957350-Indium Radioisotopes,
pubmed-meshheading:7957350-Isothiocyanates,
pubmed-meshheading:7957350-Mice,
pubmed-meshheading:7957350-Mice, Nude,
pubmed-meshheading:7957350-Pentetic Acid,
pubmed-meshheading:7957350-Radioimmunotherapy,
pubmed-meshheading:7957350-Tissue Distribution,
pubmed-meshheading:7957350-Yttrium Radioisotopes
|
pubmed:year |
1994
|
pubmed:articleTitle |
Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA).
|
pubmed:affiliation |
Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|